Today, my guest is Lars Christian Wilde, the President, Chief Business Officer, and Co‑founder of Compass Pathways.
Compass is a “mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health.” as they describe themselves. Compass was one of the first companies engaging in a bigger vision of the substance psilocybin.
But back to Lars. He is a special guest to me since I like his open mind. I remember talking to Lars in one of our first podcasts about vaccines against depression in the future. Still an interesting thought to me, we were elaborating in this episode.
I also remember how openly Lars talked about his treatment-resistant depression and anxiety disorder and the effects it had on him and the people in his life. He told me about his treatment with psilocybin, which helped him tremendously to begin a new life with a different mental health set.
I am always a fan of people, especially entrepreneurs in the psychedelic field, that share their psychedelic experiences and are personally affected by the power of psychedelic substances.
But now on to new times at COMPASS Pathways.
In 2020 lot of things have happened at Compass Pathways. In September 2020 the company became a public company, listing its stock on Nasdaq and raising $146.6 million. Compass became one of the most exciting companies in the field.
So Lars and I catch up, what is happening in the Compass World right now,
- how does a psychedelic public company feel and work differently?
- how does the Compass and Sheppard Pratt collaboration look like, since Compass is opening a Centre of Excellence in collaboration with The Sheppard Pratt Institute for Advanced Diagnostics and Therapeutics in Baltimore, Maryland, to do more research. Their psychiatry department exists since the 1800s.
- how you can implement old research data on mental health from the beginning of psychiatry in the new psychedelic research
- how Compass works with the Charité hospital in Berlin and how to do conduct a study in times of Covid at all.
how COMP360, a psilocybin therapy trial for treatment-resistant depression designed by Compass works
Please enjoy the show and Lars Wilde!
———————-
Events and News brought to you by The New Health Club!
Great article by Michelle Janikian about how to stay connected to the psychedelic communities digitally in times of covid.
News about micro-dosing psychedelics from Imperial College. Take a look at the brand new results.
And here is an incredible event about religion and psychedelics you should not miss! Hosted by our friends Adriana Kertzer from Plant Medicine Law, author Brian Muraresku and Daan Keiman, director of ethics and advocacy at Synthesis.
“Why Religion Matters; The need for faith specific psychedelic ritual”
Adriana launched the working group Faith+Delics in September 2020 with Brian’s support to bring together Jews, Christians, and Muslims passionate about the potential role psychedelics can play in their own religions. F+D's mission is to position psychedelic experiences as a valuable addition to religious development and training and to emphasize the importance of faith-specific psychedelic training.
Aaaand there is one more thing.
The New Health Club is hosting the first CLUB HOUSE festival next week!
Watch out for your inbox in the next few days, this will be fun!
🍄 #54 - Lars Christian Wilde - On markets, psilocybin & Compass Pathways.